{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"11.600","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"993,174,320","primaryexch":"香港交易所","ric":"1672.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BFLTDL2","am":"98.78","iv":"","ew_strike":"","as":"10.340","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"10.330","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-28 00:06:03.0","lo52":"0.930","shares_issued_date":"2025年9月23日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"吳勁梓","underlying_ric":"1672.HK","hi52":"18.750","issuer_name":"歌禮製藥有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"10.200","mkt_cap":"10.26","f_aum_hkd":null,"ew_sub_per_to":"","ls":"10.340","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-1.170","aum":"","issued_shares_class_B":null,"vo":"9.27","secondary_listing_flag":false,"listing_date":"2018年8月1日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"歌禮製藥有限公司 - B","nm_s":"歌禮製藥－Ｂ","sym":"1672","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"歌禮製藥有限公司是一家主要從事醫藥產品研發、生產和銷售的投資控股公司。該公司專注於病毒性疾病、非酒精性脂肪性肝炎（NASH）或原發性膽汁性膽管炎（PBC）及腫瘤領域。該公司的產品管線包括用於慢性乙肝功能性治癒的ASC22、用於呼吸道合胞病毒（RSV）的ASC10、用於人類免疫缺陷病毒（HIV）功能性治癒的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用於實體瘤的ASC61、用於中、重度痤瘡的ASC40等。該公司在國內和國外市場開展業務。","op":"11.600","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>皇后大道東248號<br/>陽光中心<br/>40樓","pc":"-10.17","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"11.510","isin":"KYG0520K1094","moneyness":""}},"qid":"1759074154728"}
